Considerations on the mechanics and sample sizes for early trials of targeted agents and immunotherapy in oncology

References

• Theoret MR, Pai-Scherf LH, Chuk MK, et al. Expansion cohorts in first-in-human solid tumor oncology trials. Clin Cancer Res off J Am Assoc Cancer Res. 2015 October 15;21(20):4545–4551. PubMed PMID: 26473190.
   PubMed Web of Science ®Google Scholar
• Woodcock J, LaVange LM, Drazen JM. master protocols to study multiple therapies, multiple diseases, or both. N Engl J Med. 2017 July 6;377(1):62–70. PubMed PMID: 28679092.
   PubMed Web of Science ®Google Scholar
• Garralda E, Dienstmann R, Piris-Gimenez A, et al. New clinical trial designs in the era of precision medicine. Mol Oncol. 2019 March;13(3):549–557. PubMed PMID: 30698321; PubMed Central PMCID: PMCPMC6396357.
   PubMed Web of Science ®Google Scholar
• Hobbs BP, Barata PC, Kanjanapan Y, et al. Seamless designs: current practice and considerations for early-phase drug development in oncology. J Natl Cancer Inst. 2019 February 1;111(2):118–128. PubMed PMID: 30561713; PubMed Central PMCID: PMCPMC6376915.
   PubMedGoogle Scholar
• U.S. Department of Health and Human Services. Food and drug administration. expansion cohorts: use in first-in-human clinical trials to expedite development of oncology drugs and biologics guidance for industry. Draft Guidance. August 2018, Available at. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/expansion-cohorts-use-first-human-clinical-trials-expedite-development-oncology-drugs-and-biologics Accessed 2021 Jan 18).
   Google Scholar
• Le Tourneau C, Lee JJ, Siu LL. Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst. 2009 May 20;101(10):708–720. PubMed PMID: 19436029; PubMed Central PMCID: PMC2684552.
   PubMedGoogle Scholar
• Wirth LJ, Sherman E, Robinson B, et al. Efficacy of Selpercatinib in RET-altered thyroid cancers. N Engl J Med. 2020 August 27;383(9):825–835. PubMed PMID: 32846061.
   PubMed Web of Science ®Google Scholar
• Yan F, Thall PF, Lu KH, et al. Phase I-II clinical trial design: a state-of-the-art paradigm for dose finding. Ann Oncol. 2018 March 1;29(3):694–699. PubMed PMID: 29267863; PubMed Central PMCID: PMCPMC5888967.
   PubMed Web of Science ®Google Scholar
• Ezzalfani M, Dugue A, Mollevi C, et al. [The role of the expansion cohort in phase I trials in oncology: guidelines of the phase I HUB]. Bull Cancer. 2015 January;102(1):73–82. PubMed PMID: 25609488.
   PubMed Web of Science ®Google Scholar
• Iasonos A, O’Quigley J. Design considerations for dose-expansion cohorts in phase I trials. J Clin Oncol. 2013 November 1;31(31):4014–4021. PubMed PMID: 24101039; PubMed Central PMCID: PMCPMC4979131.
   PubMed Web of Science ®Google Scholar
• Manji A, Brana I, Amir E, et al. Evolution of clinical trial design in early drug development: systematic review of expansion cohort use in single-agent phase I cancer trials. J Clin Oncol. 2013 November 20;31(33):4260–4267. PubMed PMID: 24127441.
   PubMed Web of Science ®Google Scholar
• Bugano DDG, Hess K, Jardim DLF, et al. Use of expansion cohorts in phase i trials and probability of success in phase ii for 381 anticancer drugs. Clin Cancer Res off J Am Assoc Cancer Res. 2017 August 1;23(15):4020–4026. PubMed PMID: 28377482; PubMed Central PMCID: PMCPMC5540786.
   PubMed Web of Science ®Google Scholar
• Norris RE, Behtaj M, Fu P, et al. Evaluating the role of phase I expansion cohorts in oncologic drug development. Invest New Drugs. 2017 February;35(1):108–114. PubMed PMID: 27718038.
   PubMed Web of Science ®Google Scholar
• Domchek SM, Postel-Vinay S, Im SA, et al. Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study. Lancet Oncol. 2020 September;21(9):1155–1164. PubMed PMID: 32771088.
   PubMed Web of Science ®Google Scholar
• Guo C, Chenard-Poirier M, Roda D, et al. Intermittent schedules of the oral RAF-MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study. Lancet Oncol. 2020 November;21(11):1478–1488. PubMed PMID: 33128873.
   PubMed Web of Science ®Google Scholar
• Jhaveri K, Chang MT, Juric D, et al. Phase I basket study of taselisib, an isoform-selective PI3K inhibitor, in patients with PIK3CA-mutant cancers. Clin Cancer Res off J Am Assoc Cancer Res. 2020 November 4. DOI:10.1158/1078-0432.CCR-20-2657. [ PubMed PMID: 33148674].
   Google Scholar
• Khoja L, Butler MO, Kang SP, et al. Pembrolizumab. J Immunother Cancer. 2015;3(1):36. PubMed PMID: 26288737; PubMed Central PMCID: PMCPMC4539882
   PubMedGoogle Scholar
• Saad ED, Paoletti X, Burzykowski T, et al. Precision medicine needs randomized clinical trials. Nat Rev Clin Oncol. 2017 May;14(5):317–323. PubMed PMID: 28169302.
   PubMed Web of Science ®Google Scholar
• Weber JS, Levit LA, Adamson PC, et al. American society of clinical oncology policy statement update: the critical role of phase I trials in cancer research and treatment. J Clin Oncol. 2015 January 20;33(3):278–284. PubMed PMID: 25512456; PubMed Central PMCID: PMC4516884.
   PubMed Web of Science ®Google Scholar
• Roberts TG Jr., Goulart BH, Squitieri L, et al. Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials. Jama. 2004 November 3;292(17):2130–2140. PubMed PMID: 15523074.
   PubMed Web of Science ®Google Scholar
• Blumenthal GM, Pazdur R. Response rate as an approval end point in oncology: back to the future. JAMA Oncol. 2016 June 1;2(6):780–781. PubMed PMID: 26913938.
   PubMed Web of Science ®Google Scholar
• Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989 March;10(1):1–10. PubMed PMID: 2702835
   PubMedGoogle Scholar
• Ratain MJ, Karrison TG. Testing the wrong hypothesis in phase II oncology trials: there is a better alternative. Clin Cancer Res off J Am Assoc Cancer Res. 2007 February 1;13(3):781–782. PubMed PMID: 17289865.
   PubMed Web of Science ®Google Scholar
• Vickers AJ, Ballen V, Scher HI. Setting the bar in phase II trials: the use of historical data for determining “go/no go” decision for definitive phase III testing. Clin Cancer Res off J Am Assoc Cancer Res. 2007 February 1;13(3):972–976. PubMed PMID: 17277252; PubMed Central PMCID: PMCPMC2529160.
   PubMed Web of Science ®Google Scholar
• Langer CJ, Gadgeel SM, Borghaei H, et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol. 2016 November;17(11):1497–1508. PubMed PMID: 27745820; PubMed Central PMCID: PMCPMC6886237.
   PubMed Web of Science ®Google Scholar
• Gandhi L, Rodriguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018 May 31;378(22):2078–2092. PubMed PMID: 29658856.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Penkov K, Haanen J, et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019 March 21;380(12):1103–1115. PubMed PMID: 30779531; PubMed Central PMCID: PMCPMC6716603.
   PubMed Web of Science ®Google Scholar
• Powles T, Plimack ER, Soulieres D, et al. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. Lancet Oncol. 2020 December;21(12):1563–1573. PubMed PMID: 33284113.
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Powles T, Burotto M, et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2021 March 4;384(9):829–841. PubMed PMID: 33657295.
   PubMed Web of Science ®Google Scholar
• Roy AC, Park SR, Cunningham D, et al. A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma. Ann Oncol. 2013 June;24(6):1567–1573. PubMed PMID: 23406728.
   PubMed Web of Science ®Google Scholar
• Lee KW, Kim BJ, Kim MJ, et al. A multicenter randomized phase ii study of docetaxel vs. docetaxel plus cisplatin vs. docetaxel plus S-1 as second-line chemotherapy in metastatic gastric cancer patients who had progressed after cisplatin plus either S-1 or capecitabine. Cancer Res Treat. 2017 July;49(3):706–716. PubMed PMID: 27764906; PubMed Central PMCID: PMCPMC5512362.
   PubMed Web of Science ®Google Scholar
• Koyama T, Chen H. Proper inference from Simon’s two-stage designs. PubMed PMID: 17960777; PubMed Central PMCID: PMCPMC6047527. Statistics in medicine. 2008 July 20;27(16):3145–3154.
   PubMed Web of Science ®Google Scholar
• Fleming TR. One-sample multiple testing procedure for phase II clinical trials. Biometrics. 1982 March;38(1):143–151. PubMed PMID: 7082756
   PubMed Web of Science ®Google Scholar
• Sargent DJ, Chan V, Goldberg RM. A three-outcome design for phase II clinical trials. Control Clin Trials. 2001 April;22(2):117–125. PubMed PMID: 11306150
   PubMedGoogle Scholar
• O’Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics. 1979 September;35(3):549–556. PubMed PMID: 497341
   PubMed Web of Science ®Google Scholar
• Jung SH. Randomized phase II trials with a prospective control. Stat Med. 2008 February 20;27(4):568–583. PubMed PMID: 17573688.
   PubMed Web of Science ®Google Scholar
• Cunanan KM, Gonen M, Shen R, et al. Basket trials in oncology: a trade-off between complexity and efficiency. J Clin Oncol. 2017 January 20;35(3):271–273. PubMed PMID: 27893325; PubMed Central PMCID: PMCPMC5559900.
   PubMed Web of Science ®Google Scholar
• Simon R, Geyer S, Subramanian J, et al. The Bayesian basket design for genomic variant-driven phase II trials. Semin Oncol. 2016 February;43(1):13–18. PubMed PMID: 26970120.
   PubMed Web of Science ®Google Scholar